NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Pharmacyte Biotech, Inc. PMCB
15 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
$3.19
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
77.1%
Net margin · FY24
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2024 · full 15-year series below
Revenue
Net income
Per share
USD 3.19
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
77.1%
Return on equity, FY2024
ROE
Operating margin—
Net margin—
Return on assets53.3%
Each USD of equity produced 77 cents of profit this year.
Returned to shareholders
USD 2.5M
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 2.5M
Share of profit8.3%
Consecutive raises—
USD 2.5M in buybacks — 8% of the year's profit went back to shareholders.
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years+71.7%
Change, 10 years—
The share count grew 72% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 55.2M
total assets, end of FY2024
Total assetsUSD 55.2M
EquityUSD 51.9M
CashUSD 15.2M
Current ratio7.68×
Equity funds 94% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
3.19
−1.80
−0.22
−0.27
−2.45
−4.23
0.00
−0.01
−0.01
−0.01
−0.01
−0.05
0.00
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
77.1
0.7
−5.3
−8.8
−60.4
−75.6
−75.3
−98.6
−60.8
−84.8
−118.8
−732.5
·
·
·
Shares out B
0.01
0.01
0.02
0.02
0.00
0.00
1.19
1.01
0.91
0.78
0.73
0.69
0.48
0.42
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed